Home / Peptides / Bremelanotide
Bremelanotide (PT-141) Dosage Chart and Schedule
FDA-approved
Melanocortin agonist (Vyleesi) approved for low sexual desire in premenopausal women. 1.75 mg as needed.
Also called: PT-141, Vyleesi
Regulatory status (US)
FDA-approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not the same drug as melanotan II.
What it is
A melanocortin receptor agonist, a cyclic peptide related to alpha-MSH.
Label dose (Vyleesi)
| Dose | When | Limits |
|---|---|---|
| 1.75 mg under the skin (autoinjector) | At least 45 minutes before sexual activity | No more than 1 dose in 24 hours; more than 8 doses a month is not recommended |
From the Vyleesi prescribing information. Stop after 8 weeks if there is no improvement.
Bremelanotide reconstitution calculator
Enter your vial and your prescribed dose to see the units on a U-100 syringe.
What human studies show
- Approved on the basis of two phase 3 trials in premenopausal women with HSDD.
Safety
- Blood pressure rises and heart rate drops briefly after each dose; do not use with uncontrolled high blood pressure or known heart disease.
- Can cause dark patches on the skin, more often with more than 8 doses a month.
- Nausea in about 40% of users.
Questions
- Is Bremelanotide FDA-approved?
- FDA-approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not the same drug as melanotan II.
- What dose of Bremelanotide has been studied?
- 1.75 mg under the skin (autoinjector): At least 45 minutes before sexual activity: No more than 1 dose in 24 hours; more than 8 doses a month is not recommended. From the Vyleesi prescribing information. Stop after 8 weeks if there is no improvement.
- How many units is my Bremelanotide dose?
- Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.
Related
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Sources
- Vyleesi (bremelanotide) prescribing information (Drugs.com label mirror)
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
Last checked 2026-11-16. How we pick and check sources: methodology.